Mesoblastic Nephroma is a type of kidney tumor that is usually found in babies and young children. It's a solid mass of cells that grows in the kidney. Most of these tumors are harmless (benign) and often disappear on their own, but doctors need to monitor them.
Every report comes from a Lived member, sent anonymously.
Have you had Nephrectomy for Mesoblastic Nephroma?
Mesoblastic nephroma, usually called congenital mesoblastic nephroma, is a rare kidney tumor that forms before birth or in the first months of life. It is the most common kidney tumor in babies younger than 6 months, and most cases are found by about 3 months of age. It usually grows as a single mass in one kidney. Doctors describe it as a tumor with low malignant potential: it rarely spreads, and removing it with surgery cures most babies. It is not the same as Wilms tumor, the most common kidney cancer of childhood, although the two can look alike on scans. Wilms tumor becomes more likely than mesoblastic nephroma as a baby gets older than about 2 months. There are three subtypes, identified when a pathologist examines the removed tumor under a microscope. The classic type has fewer, evenly spread cells. The cellular type is more densely packed, tends to be larger, and is the same tumor as infantile fibrosarcoma (a rare soft-tissue tumor of babies) arising in the kidney. The mixed type has features of both. The subtype matters because it helps predict the small chance that the tumor comes back.
Mesoblastic nephroma begins while the baby is developing in the womb. Boys are diagnosed about twice as often as girls. Beyond that, no cause or risk factor has been firmly established. Most cellular tumors carry a gene fusion, a change in the tumor's own cells in which two genes (most often ETV6 and NTRK3) are joined together and drive the tumor's growth. Finding this change helps confirm the diagnosis and can point to targeted medicines if the tumor ever returns. Classic tumors usually lack this fusion.
More than 15% of cases are spotted before birth on an ultrasound. Often the first clue is too much amniotic fluid around the baby (polyhydramnios), which prompts a detailed scan in the second half of pregnancy. Cases found before birth are mostly seen in the third trimester or late in the second trimester, not at the routine mid-pregnancy scan. After birth, a baby may have a firm, swollen belly or a mass a doctor can feel. Some babies have high blood pressure, blood in the urine or, less often, a high calcium level in the blood caused by substances the tumor releases. Ultrasound is usually the first test, followed by CT or MRI to show the tumor's size and its relationship to nearby blood vessels and organs. Scans cannot reliably tell mesoblastic nephroma from Wilms tumor. For a tumor that can be removed, specialists generally do not take a biopsy first, because a biopsy by itself places the tumor in a higher stage, which can lead to extra treatment. Instead, the diagnosis and subtype are confirmed when the removed kidney is examined, sometimes with a test for the gene fusion. Doctors also assign a stage based on whether the tumor was removed completely and whether any of it spilled during surgery.
The standard treatment is surgery to remove the affected kidney and tumor together (nephrectomy). For most babies, this is the only treatment needed. Because surgery and anesthesia carry more risk in the first weeks of life, the timing and approach are planned carefully, ideally at a children's hospital with pediatric cancer surgeons and specialists experienced with infant kidney tumors. Chemotherapy is not routine. It may be used before surgery to shrink a very large tumor that would be hard to remove safely; in one large European series, about 6 in 10 babies treated this way had measurable shrinkage. After surgery, some specialists recommend chemotherapy for the cellular subtype when tumor was left behind or spilled (stage III), particularly in babies 3 months or older. Evidence for this comes from small groups of children, and some infants younger than 2 months may not need it. If the tumor comes back, treatment is individualized and may combine further surgery, chemotherapy and sometimes radiation. When the tumor carries an NTRK gene fusion, targeted medicines called TRK inhibitors, larotrectinib (Vitrakvi) and entrectinib (Rozlytrek), are an option (entrectinib from 1 month of age). They block the signal the fusion produces and are approved for solid tumors with this fusion when surgery would be too harmful or other treatments have not worked.
The outlook is excellent. In large studies, about 94% of children have no further problems after treatment and about 97% survive. Most babies recover from surgery and grow and develop normally. The main concern after surgery is the small chance that the tumor returns, usually at the original site. In a large North American study, no child with a classic-type tumor or a stage I tumor of any type relapsed. The risk was concentrated in larger cellular or mixed tumors that were not fully contained at surgery, where roughly 7 to 16 in 100 children relapsed. When a relapse happens it is serious, and some children die despite further treatment, which is why follow-up for higher-risk children matters. Relapses tend to happen early, many within 3 months and nearly all within 12 to 18 months. Children with higher-risk tumors usually have scans of the belly and chest about every 3 months during that period, often with ultrasound and chest X-ray to limit radiation in young babies. Children with low-risk tumors may need little or no ongoing imaging.
During pregnancy, a scan that shows extra amniotic fluid or a kidney mass in the baby should be discussed with the obstetric team, since a baby with this tumor is more likely to be born early and may benefit from referral to a specialist center before delivery. In an infant, a swollen belly, a lump in the abdomen or blood in the urine should be checked by a doctor promptly. After treatment, keep every scheduled scan and tell the care team about new belly swelling, poor feeding or other changes between visits, especially in the first year or so.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Mesoblastic Nephroma is like, what's helped you, or ask the community a question.